A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 47/42 (2006.01) A61K 9/20 (2006.01) A61K 9/22 (2006.01) A61K 47/36 (2006.01)
Patent
CA 2140032
The present application is concerned with a solid slow release pharmaceutical dosage unit. More specifically, the invention is directed to a tablet form prepared by direct compression of cross-linked amylose (CLA) having a definite cross-linking degree, .alpha.-amylase and a pharmaceutical agent. The presence of the cross-linked amylose allows a sustained release of the drug, while the .alpha.-amylase permits the modulation of the release time. In other words, the release time of the drug is function of the amount of .alpha.-amylase in the tablet. The amount of amylase is defined in terms of Enzyme Units.
La présente application concerne une unité de dose pharmaceutique à libération lente solide. Plus précisément, il s'agit d'un comprimé préparé par compression pure d'une amylose réticulée ayant un degré de réticulation défini, d'une alpha-amylase et d'un agent pharmaceutique. La présence de l'amylose réticulée permet une libération prolongée du médicament, et l'alpha-amylase permet une modulation du temps de libération. En d'autres mots, le temps de libération du médicament est fonction de la quantité d'alpha-amylase dans le comprimé. La quantité d'amylase est définie selon le concept des unités enzymatiques.
Cartilier Louis
Dumoulin Yves
Lenaerts Vincent
Mateescu Mircea A.
Borden Ladner Gervais Llp
Labopharm Inc.
LandOfFree
Cross-linked amylose material for enzymatically controlled... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cross-linked amylose material for enzymatically controlled..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cross-linked amylose material for enzymatically controlled... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1820496